Cue Biopharma, Inc. (CUE)
| Market Cap | 393.62M |
| Revenue (ttm) | 3.73M |
| Net Income (ttm) | -42.60M |
| Shares Out | 29.65M |
| EPS (ttm) | -1.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 2 |
| Last Price | $13.00 |
| Previous Close | $13.35 |
| Change ($) | -0.35 |
| Change (%) | -2.62% |
| Day's Open | 13.52 |
| Day's Range | 12.95 - 13.86 |
| Day's Volume | 151,216 |
| 52-Week Range | 9.30 - 31.69 |
CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to ...
Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs
Insider buying is often a profitable signal for bulls. Insiders only buy for one reason: they believe their company's stock is going higher.
Cue Biopharma is a clinical-stage biopharmaceutical company developing novel injectables that modulate targeted T-cells. Cue Biopharma has expanded its pipeline to include 7 therapeutics with ...
Investors need to pay close attention to Cue Biopharma (CUE) stock based on the movements in the options market lately.
CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to ...
CAMBRIDGE, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selective...
CAMBRIDGE, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to ...
CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selective...
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selective...
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selective...
CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selective...
Appointment augments board capabilities with a seasoned business development executive as Cue Biopharma executes its next stage of corporate development
Novel positron emission tomography approach demonstrates the ability of Immuno-STAT based scaffolds to selectively engage tissue-resident T cells including intratumoral T cells of defined spec...
Cue Biopharma (CUE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to sele...
Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2020 Results - Earnings Call Transcript
CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selec...
CAMBRIDGE, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selec...
CAMBRIDGE, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selec...
Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed...
- Novel insights into receptor binding events and interfaces have led to generation of selective molecules with unique biochemical and functional properties through an effort led by Dr. Steven...
CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed...
Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q1 2020 Results - Earnings Call Transcript
CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to select...
CAMBRIDGE, Mass., May 18, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to select...
Collaboration to Study Immuno-STAT Biologics on T Cell Immunological Synapse Formation Using the IL-2-Based CUE-100 Series
Dynamic New Players Gain Momentum In Digital, Data And Patient-Centric Space
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.
Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q4 2019 Results - Earnings Call Transcript
Cue Biopharma (CUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Cue Biopharma, Inc. (CUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Cue Biopharma: An Innovative But Risky Immunology Pick For 2020
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Concept-proving results for lead programs at these biotechs will send their stock prices soaring or sinking before the year's over.
CAMBRIDGE, Mass., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selec...
U.S. stocks rallied to attained fresh all-time highs in 2019, as the momentum continued in 2020. Here are five stocks that are poised to grow.
Does Cue Biopharma, Inc. (CUE) have what it takes to be a top stock pick for momentum investors?
The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.
Does Cue Biopharma, Inc. (CUE) have what it takes to be a top stock pick for momentum investors?
As of late, it has definitely been a great time to be an investor in Cue Biopharma, Inc. (CUE).
Cue Biopharma, Inc. (CUE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selec...
Change represents evolving board capabilities as Cue Biopharma enters next stage of its corporate development Change represents evolving board capabilities as Cue Biopharma enters next stage o...
CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selec...
Company Integrates Operational Oversight with Dr. Suri’s Expertise in Immunology Company Integrates Operational Oversight with Dr. Suri’s Expertise in Immunology
About CUE
Cue Biopharma, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, an onco-fetal viral antigen for cancers, including solid tumors and hematologic malignancies; CUE-103, an antigen; CUE-200 frame... [Read more...]
| Industry Biotechnology | IPO Date Jan 2, 2018 |
| CEO Daniel Passeri | Employees 45 |
| Stock Exchange NASDAQ | Ticker Symbol CUE |
Financial Performance
In 2019, Cue Biopharma's revenue was $3.46 million, an increase of 202.67% compared to the previous year's $1.14 million. Losses were -$36.70 million, -5.85% less than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for Cue Biopharma stock is "Strong Buy." The 12-month stock price forecast is 30.00, which is an increase of 130.77% from the latest price.